Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Forrest Allen

Interventional Pain Medicine Nashville, TN Doctor of Osteopathy

NPI 1295081065 CMS profile 770876

2011 Murphy Ave Ste 301, Nashville, TN 37203

Open in the dashboard

General payments

$8,110

150 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Forrest Allen of Nashville, TN is reported in the CMS Open Payments database as having received $8,110 across 150 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,486 28
2024 General $843 18
2023 General $638 14
2022 General $663 24
2021 General $3,771 46
2020 General $281 13
2019 General $428 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Forrest Allen
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Forrest Allen were reported at $1,486. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Forrest Allen Interventional Pain Medicine median Middle half National median
2019 $428 $684 $216–$2,079 $163
2020 $281 $382 $122–$1,109 $114
2021 $3,771 $552 $167–$1,554 $132
2022 $663 $605 $187–$1,924 $149
2023 $638 $671 $195–$1,915 $160
2024 $843 $684 $206–$1,837 $164
2025 $1,486 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Spinal Simplicity, LLC $1,798 7 payments
  2. Medtronic, Inc. $1,061 16 payments
  3. Boston Scientific Corporation $994 22 payments
  4. Curonix LLC $826 15 payments
  5. Abbott Laboratories $661 24 payments
  6. Nevro Corp. $540 8 payments
  7. Pacira Pharmaceuticals Incorporated $427 8 payments
  8. Stimwave Technologies Incorporated $369 4 payments
  9. Relievant Medsystems, Inc. $257 7 payments
  10. SPR Therapeutics, Inc $253 8 payments
  11. Other $925 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,449 147 payments
  2. Travel and Lodging $1,661 3 payments
Products named General payments · program years 2019–2025
  1. HA MINUTEMAN G3-R $1,798 7 payments
  2. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $826 15 payments
  3. WaveWriter Alpha Prime 16 $720 17 payments
  4. INTELLIS ADAPTIVESTIM $544 11 payments
  5. Omnia $512 7 payments
  6. Proclaim IPG $414 12 payments
  7. INTELLIS $390 4 payments
  8. Iovera System $310 4 payments
  9. SPRINT PNS System $253 8 payments
  10. mild Device Kit $192 4 payments
  11. Other $2,315 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

320

Median for Interventional Pain Management: 1,220

Drug cost

$1,643

Median for Interventional Pain Management: $39,344

Branded share of claims

24.4%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 57 $504
Tizanidine Hcl Generic 92 $287
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 21 $256
Gabapentin Generic 30 $209
Tramadol Hcl Generic 57 $176
Meloxicam Generic 27 $87
Cyclobenzaprine Hcl Generic 20 $67
Cephalexin Generic 16 $57

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$229,407

Of which drugs: $2,572

Medicare patients

584

Average age 75

Services billed

5,992

359 women, 225 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 36%
Diabetes 28%
Chronic kidney disease 27%
Depression 26%
COPD 18%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 76 3,157 $314
Injection, methylprednisolone acetate, 40 mg J1030 Office 54 56 $252

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

150 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record